Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H2 2016', provides in depth analysis on Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1)
- The report reviews Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential ands scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) Overview 7
Therapeutics Development 8
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Products under Development by Stage of Development 8
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Products under Development by Therapy Area 9
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Products under Development by Indication 10
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Products under Development by Companies 14
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development 24
Advenchen Laboratories LLC 24
Aslan Pharmaceuticals Pte Ltd 25
Astellas Pharma Inc 26
Bristol-Myers Squibb Company 27
Lead Discovery Center GmbH 28
Pfizer Inc 29
SignalChem Lifesciences Corp 30
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Drug Profiles 31
AL-2846 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
ASLAN-005 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
BMS-777607 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
crizotinib - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
OSI-296 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecules to Antagonize RON Kinase for Pancreatic Cancer - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecules to Inhibit MST1R for Oncology - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecules to Inhibit RON Kinase for Oncology - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Dormant Projects 45
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Discontinued Products 46
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Featured News & Press Releases 47
Nov 10, 2016: NICE publishes draft guidance recommending crizotinib 47
Nov 07, 2016: FDA approves Roche's VENTANA ALK (D5F3) CDx Assay for use on the VENTANA BenchMark ULTRA system 47
Oct 17, 2016: Gene fusion opens up treatment possibilities for aggressive brain cancer 47
Aug 31, 2016: XALKORI (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer 49
Aug 17, 2016: NICE recommends crizotinib, first pill for lung cancer 50
Jul 21, 2016: CHMP adopts extension to existing therapeutic indication for Xalkori 50
Jun 14, 2016: AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer 51
Jun 03, 2016: Crizotinib Demonstrates Clinical Benefit in Phase II Study of East Asian Patients with ROS1-Positive Non-Small Cell Lung Cancer 51
Mar 11, 2016: XALKORI (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer 52
Dec 08, 2015: Pfizer Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for XALKORI (crizotinib) for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer 53
Nov 25, 2015: Pfizer Receives European Approval to Expand Use of XALKORI (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer 54
Nov 18, 2015: Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer 55
Sep 08, 2015: Study defines criteria for MET-driven lung cancer suitable for crizotinib treatment 55
Apr 21, 2015: Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer 57
Mar 16, 2015: ASLAN announces positive phase 1 results with ASLAN002 57

Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 5

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 (Contd..1) 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by Advenchen Laboratories LLC, H2 2016 24
Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 25
Pipeline by Astellas Pharma Inc, H2 2016 26
Pipeline by Bristol-Myers Squibb Company, H2 2016 27
Pipeline by Lead Discovery Center GmbH, H2 2016 28
Pipeline by Pfizer Inc, H2 2016 29
Pipeline by SignalChem Lifesciences Corp, H2 2016 30
Dormant Projects, H2 2016 45
Discontinued Products, H2 2016 46